Malattia di Crohn e colite ulcerosa, lo studio Podcast di AbbVie fa luce su patologie ‘invisibili’
(Adnkronos) - videnziano la necessità di un ulteriore sforzo terapeutico per sostenere i pazienti con malattie infiammatorie croniche intestinali (Mici) e di una maggiore comunicazione tra medico e paziente i dati presentati a Milano all’evento ‘Malattia di Crohn e colite ulcerosa: diamo luce all’invisibile’ organizzata da Abbvie, relativi allo studio osservazionale Podcast, curato dalla farmaceutica e dell'indagine sui pazienti Acquire-Ibd, realizzata dall’Associazione nazionale per le malattie infiammatorie croniche dell’intestino (Amici Ets). I risultati mostrano un miglioramento dell’assistenza e della qualità di vita dei pazienti ma anche un costante stato di preoccupazione per la malattia che riguarda un paziente su tre.
Category
🗞
NewsTranscript
00:00 The inflammatory and chronic intestinal diseases affect about 250,000 people in Italy, are
00:10 a cause of disability often invisible and seriously compromise the quality of life of
00:15 patients.
00:16 The two main diseases belonging to this type are Crohn's disease and Colitis Ulcerosa,
00:21 which interest respectively 150,000 and 100,000 Italians.
00:25 It is mentioned during the press conference organized by AbbVie in Milan and entitled
00:30 "Crohn's disease and Colitis Ulcerosa, let's give light to the invisible".
00:34 "Colitis Ulcerosa is characterized by blood flow with the feces and abdominal pain,
00:41 Crohn's disease is characterized mainly and more frequently by an important diarrhea
00:47 and abdominal pain that therefore determine how easy it is to imagine a huge impact on
00:53 quality of life".
00:54 During the press conference, the results of the observational study "IbD Podcast"
00:59 presented by AbbVie and the investigation on patients "Acquire IbD" carried out by the
01:04 National Association for Inflammatory and Chronic Diseases of the Intestine, AbbVie's study
01:09 in particular, shows that half of patients with Crohn's disease and Colitis Ulcerosa
01:14 do not have an optimal control of the disease.
01:16 "There is therefore a need for further therapeutic effort for these patients.
01:21 Another relevant fact is that of the misalignment of the perception of the gravity of the disease
01:26 and therefore of well-being between patients and doctors.
01:29 There is therefore a need to fill this clinical gap, also improving communication between
01:34 doctor and patient".
01:35 Traditional therapeutic options such as mesalazine, steroids and immunosuppressants are accompanied
01:41 by the more recent ones, called advanced therapies, such as monoclonal antibodies and small molecules.
01:47 "Both monoclonal antibodies, that is, biotechnological therapies and small molecules,
01:53 must be started when the patient is not perfectly under control with conventional therapy,
01:59 which, in my opinion, is in many patients the disease is not under control and therefore
02:06 many patients would need to start an advanced therapy".
02:09 The photograph taken by the National Association for Inflammatory and Chronic Diseases of the
02:14 Intestine shows an improvement in the quality of life of patients, but also a constant
02:20 state of concern for the disease that concerns a patient out of three.
02:24 "Only 10% of patients with colitulcerosa are informed in an important way about the disease,
02:30 18% of patients affected by chronic diseases are, but there is a large number of patients
02:35 who do not know the disease very well and do not know how to manage it".